Literature DB >> 1468420

Technique for calculation of the true costs of antibiotic therapy.

J R Kerr1, J G Barr, E T Smyth, J O'Hare.   

Abstract

An in-house method for costing antibiotic therapy is presented which quantifies hidden costs including costs arising from intravenous administration, labour, serum antibiotic assay, monitoring of haematological and biochemical indices and disposal of sharp instruments. A study of various hospital procedures relating directly to antibiotic therapy was undertaken in an acute medical ward, which involved determination of staff members performing various procedures, consumables used and time taken. Results of this study facilitated accurate quantification of hidden costs of i.v. antibiotic therapy in this ward. Using these results, the cost of five-day courses of gentamicin, cefuroxime, penicillin G, flucloxacillin and erythromycin were calculated. The costing of adverse effects was not attempted. It is recommended that a costing technique of this sort is used in cost-benefit analysis of antibiotic use, as the cost of the drug alone is misleading.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1468420     DOI: 10.1007/bf01960882

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  4 in total

1.  Unnecessary and ecological cost of hospital infection.

Authors:  F Daschner
Journal:  J Hosp Infect       Date:  1991-06       Impact factor: 3.926

Review 2.  Antimicrobial therapy. Cost-benefit considerations.

Authors:  B J Guglielmo; G F Brooks
Journal:  Drugs       Date:  1989-10       Impact factor: 9.546

3.  Human and non-financial costs of hospital-acquired infection.

Authors:  P Davey; C Hernanz; W Lynch; M Malek; D Byrne
Journal:  J Hosp Infect       Date:  1991-06       Impact factor: 3.926

4.  What is the cost of nephrotoxicity associated with aminoglycosides?

Authors:  J M Eisenberg; H Koffer; H A Glick; M L Connell; L E Loss; G H Talbot; N H Shusterman; B L Strom
Journal:  Ann Intern Med       Date:  1987-12       Impact factor: 25.391

  4 in total
  8 in total

Review 1.  Treatment of urinary tract infection. Clinical and economic considerations.

Authors:  R J Plumridge; C L Golledge
Journal:  Pharmacoeconomics       Date:  1996-04       Impact factor: 4.981

2.  Hidden costs of antibiotics.

Authors:  E T Smyth; J G Barr; G M Hogg
Journal:  Pharmacoeconomics       Date:  1996-07       Impact factor: 4.981

Review 3.  Oral ciprofloxacin: a pharmacoeconomic evaluation of its use in the treatment of serious infections.

Authors:  J A Balfour; D Faulds
Journal:  Pharmacoeconomics       Date:  1993-05       Impact factor: 4.981

4.  An assessment of the hidden and total antibiotic costs of four parenteral cephalosporins.

Authors:  E T Smyth; J G Barr; C A O'Neill; G M Hogg
Journal:  Pharmacoeconomics       Date:  1995-12       Impact factor: 4.981

5.  Cost comparison of antibacterial therapies for serious infections. A New Zealand 3-hospital study.

Authors:  W G Scott; H M Scott; S Henderson; A Inder; J Sanders; R Spearing; C McArthur; J Judson; B Baker; P Hicks; P Cotterell
Journal:  Pharmacoeconomics       Date:  1999-08       Impact factor: 4.981

6.  Computerised calculation of the true costs of antibiotic therapy.

Authors:  J R Kerr; J G Barr; E T Smyth
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-08       Impact factor: 3.267

7.  Meropenem. A pharmacoeconomic review of its use in serious infections.

Authors:  S M Holliday; P Benfield
Journal:  Pharmacoeconomics       Date:  1998-03       Impact factor: 4.981

8.  Daily antibiotic cost of nosocomial infections in a Turkish university hospital.

Authors:  Dilara Inan; Rabin Saba; Filiz Gunseren; Gozde Ongut; Ozge Turhan; Ata Nevzat Yalcin; Latife Mamikoglu
Journal:  BMC Infect Dis       Date:  2005-01-31       Impact factor: 3.090

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.